Literature DB >> 20686423

Renal Fanconi syndrome secondary to deferasirox: where there is smoke there is fire.

Michel Baum.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20686423      PMCID： PMC2950869          DOI： 10.1097/MPH.0b013e3181ec0c4d

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN： 1077-4114            Impact factor:   1.289


× No keyword cloud information.
  8 in total

1.  Role of adenosine triphosphate (ATP) and NaK ATPase in the inhibition of proximal tubule transport with intracellular cystine loading.

Authors:  C Coor; R F Salmon; R Quigley; D Marver; M Baum
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

2.  Deferasirox treatment may be associated with reversible renal Fanconi syndrome.

Authors:  Ehud Even-Or; Rachel Becker-Cohen; Hagit Miskin
Journal:  Am J Hematol       Date:  2010-02       Impact factor: 10.047

3.  Charge states of deferasirox-ferric iron complexes.

Authors:  Robert C Hider
Journal:  Am J Kidney Dis       Date:  2010-03       Impact factor: 8.860

4.  Acquired proximal renal tubular dysfunction in β-thalassemia patients treated with deferasirox.

Authors:  Joanne Yacobovich; Pinhas Stark; Shlomit Barzilai-Birenbaum; Irit Krause; Idit Pazgal; Isaac Yaniv; Hannah Tamary
Journal:  J Pediatr Hematol Oncol       Date:  2010-10       Impact factor: 1.289

5.  Iron-dependent changes in cellular energy metabolism: influence on citric acid cycle and oxidative phosphorylation.

Authors:  H Oexle; E Gnaiger; G Weiss
Journal:  Biochim Biophys Acta       Date:  1999-11-10

6.  Acute renal failure and Fanconi syndrome due to deferasirox.

Authors:  Steven Grangé; Dominique M Bertrand; Dominique Guerrot; Florence Eas; Michel Godin
Journal:  Nephrol Dial Transplant       Date:  2010-04-20       Impact factor: 5.992

7.  A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.

Authors:  Maria Domenica Cappellini; Alan Cohen; Antonio Piga; Mohamed Bejaoui; Silverio Perrotta; Leyla Agaoglu; Yesim Aydinok; Antonis Kattamis; Yurdanur Kilinc; John Porter; Marcello Capra; Renzo Galanello; Slaheddine Fattoum; Guillermo Drelichman; Carmelo Magnano; Monica Verissimo; Miranda Athanassiou-Metaxa; Patricia Giardina; Alexandra Kourakli-Symeonidis; Gritta Janka-Schaub; Thomas Coates; Christiane Vermylen; Nancy Olivieri; Isabelle Thuret; Herbert Opitz; Catherine Ressayre-Djaffer; Peter Marks; Daniele Alberti
Journal:  Blood       Date:  2005-12-13       Impact factor: 22.113

8.  Fanconi syndrome due to deferasirox.

Authors:  Cédric Rafat; Fadi Fakhouri; Jean-Antoine Ribeil; Richard Delarue; Moglie Le Quintrec
Journal:  Am J Kidney Dis       Date:  2009-06-03       Impact factor: 8.860
  8 in total
  7 in total

1.  Anticonvulsant-induced rickets and nephrocalcinosis.

Authors:  Keith K Lau; Koyelle Papneja
Journal:  BMJ Case Rep       Date:  2012-02-25

2.  A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload.

Authors:  Ellis J Neufeld; Renzo Galanello; Vip Viprakasit; Yesim Aydinok; Antonio Piga; Paul Harmatz; Gian Luca Forni; Farrukh T Shah; Rachael F Grace; John B Porter; John C Wood; Jennifer Peppe; Amber Jones; Hugh Young Rienhoff
Journal:  Blood       Date:  2012-01-17       Impact factor: 22.113

3.  A Case of Drug-Induced Proximal Tubular Dysfunction.

Authors:  Andrew M Hall; Robert J Unwin
Journal:  Clin J Am Soc Nephrol       Date:  2019-06-10       Impact factor: 8.237

Review 4.  Deferasirox nephrotoxicity-the knowns and unknowns.

Authors:  Juan Daniel Díaz-García; Angel Gallegos-Villalobos; Liliana Gonzalez-Espinoza; Maria D Sanchez-Niño; Jesus Villarrubia; Alberto Ortiz
Journal:  Nat Rev Nephrol       Date:  2014-07-22       Impact factor: 28.314

5.  Deferasirox-induced renal impairment in children: an increasing concern for pediatricians.

Authors:  Laurence Dubourg; Céline Laurain; Bruno Ranchin; Corinne Pondarré; Aoumeur Hadj-Aïssa; Dominique Sigaudo-Roussel; Pierre Cochat
Journal:  Pediatr Nephrol       Date:  2012-04-24       Impact factor: 3.714

Review 6.  Iron metabolism in the pathogenesis of iron-induced kidney injury.

Authors:  A M F Martines; R Masereeuw; H Tjalsma; J G Hoenderop; J F M Wetzels; D W Swinkels
Journal:  Nat Rev Nephrol       Date:  2013-05-14       Impact factor: 28.314

7.  What is known about deferasirox chelation therapy in pediatric HSCT recipients: two case reports of metabolic acidosis.

Authors:  Carmen Fucile; Francesca Mattioli; Valeria Marini; Massimo Gregori; Aurelio Sonzogni; Antonietta Martelli; Natalia Maximova
Journal:  Ther Clin Risk Manag       Date:  2018-09-07       Impact factor: 2.423
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.